Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if TVRD is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
8 top institutions tracked
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 3
58 filers reported a long position in TVRD for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Slate Path Capital LP | $1.3M | 704.1K | Unchanged |
| VANGUARD CAPITAL MANAGEMENT LLC | $654.3K | 344.4K | -0.1% |
| AMERICAN FINANCIAL GROUP INC | $425K | 223.7K | Unchanged |
| UBS Group AG | $211.2K | 111.1K | +120.3% |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $192K | 101K | Unchanged |
| BlackRock, Inc. | $181.4K | 95.5K | -75.4% |
| RENAISSANCE TECHNOLOGIES LLC | $173.7K | 91.4K | -0.8% |
| GEODE CAPITAL MANAGEMENT, LLC | $171.7K | 90.4K | -50.4% |
| MORGAN STANLEY | $147.9K | 77.8K | +6.8% |
| Duncan Williams Asset Management, LLC | $120.2K | 63.2K | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.